Our current podcast series is focused on Alzheimer’s disease biomarkers. Hundreds of studies have emerged in recent years that have aimed to characterize and validate several blood-based biomarkers and ready them for daily use in the real-world. While a number of well-studied diagnostic markers are beginning to be implemented in clinical practice, many more are still emerging. Biomarkers that can predict prognosis or be used for monitoring and outcome assessment in clinical trials are needed to improve disease management and support the development of novel therapeutics.

In this third and final episode, our guests will discuss their work on the discovery and validation of promising new biomarkers for monitoring, prognostication, and clinical trial outcomes. Novel markers beyond the classical measures of plasma amyloid and phosphorylated tau will be discussed, including TREM2, neurofilament light, retinal imaging, and blood-brain barrier leakage. It is hoped that these features could provide valuable insights beyond those provided by the current biomarker repertoire.

With Charlotte Teunissen, Amsterdam University Medical Center; Estrella Morenas-Rodriguez, German Center for Neurodegenerative Diseases; Natalia Vergara, University of Colorado School of Medicine; Giulia Giacomucci, University of Florence; and Axel Montagne, UK Dementia Research Institute.